Basın açıklamaları, Japonya'da FUJIFILM Corporation tarafından yayınlanmaktadır.
Fujifilm, bu basın açıklamalarındaki ürünlerin tüm ülkelerde ve bölgelerde ticari olarak satışta olduğuna dair hiçbir beyanda bulunmaz.
Bu web sitesinde yer alan içeriklerin basın duyurusu tarihi itibariyle güncel olduğunu ve önceden haber verilmeksizin değiştirilebileceğini lütfen unutmayın. Ürün bulunabilirliği, teknik özellikleri, fiyatlar, irtibat kişileri dahil olmak üzere her bir açıklamada yer alan bilgiler yayınlanma tarihinde geçerli olan bilgilerdir.
- Nis 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Şub 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Ara nedir: Ay adının kısaltması 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Kas 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Haz 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mar 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Ara nedir: Ay adının kısaltması 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Ara nedir: Ay adının kısaltması 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Eki 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Haz 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Nis 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mar 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product - Oca 27, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Eyl 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Ağu 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Haz 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Haz 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical) - Nis 27, 2021
- Fujifilm sets its highest record with 23 products winning the internationally prestigious “iF Design Award”